On December 28, 2020, Raily Aesthetic Medicine International Holdings Limited ("Raily Aesthetic Medicine"; Stock Code: 02135.HK) completed its IPO and listing on the Main Board of the Hong Kong Stock Exchange (HKEX). Following the listing, the company will become mainland China's first medical aesthetics and cosmetic beauty enterprise listed on HKEX.

Raily Aesthetic Medicine is a leading medical aesthetics provider in Zhejiang Province. The company offers a broad range of medical aesthetic  products to its clients to meet their different cosmetic beauty and anti-aging objectives. The company’s services include (i) cosmetic surgery services, comprising cosmetic surgical procedures performed on various parts of the face and body; (ii) minimally-invasive, cosmetic services, comprising cosmetic injection procedures; and (iii) cosmetic dermatology services, comprising various cosmetic procedures. According to Frost & Sullivan, the company was ranked fourth and fifth in terms of medical aesthetic service revenues in 2019 among its privately-owned peers in Hangzhou and Zhejiang Province respectively.

As the Chinese legal adviser to Raily Aesthetic Medicine, Jingtian & Gongcheng's legal team provided one-stop, end-to-end legal services for the company’s IPO and listing, including Chinese legal due diligence, restructuring, identifying and arranging introductions to pre-IPO investors, offering legal opinions and assisting in answering inquiries from the regulator. In particular, the team focused on issues concerning foreign investment regulations and legal compliance of medical aesthetics institutions, and offering legal opinions to the company. The team worked with project intermediaries to overcome the impact of the COVID-19 pandemic on the project, and assisted the company in successfully listing, garnering recognition from the client.